Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the μ opioid receptor

Journal of Pharmacology and Experimental Therapeutics

Volumn 278, Issue 3, 1996, Pages 1121-1127

  Emmerson, P J ^a   Clark, M J ^a   Mansour, A ^c   Akil, H ^c   Woods, J H ^a,b   Medzihradsky, F ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTORPHANOL; CYCLAZOCINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ETONITAZENE; FENTANYL; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); LEVALLORPHAN; MORPHICEPTIN[3 (N METHYLPHENYLALANINE) 4 DEXTRO PROLINAMIDE]; MORPHINE; MU OPIATE RECEPTOR AGONIST; NALBUPHINE; NALORPHINE; NALTREXONE; PENTAZOCINE; PERTUSSIS TOXIN; PETHIDINE; PROFADOL; SUFENTANIL;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SCREENING; GLIOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; BINDING, COMPETITIVE; CELL MEMBRANE; ENZYME ACTIVATION; GLIOMA; GTP-BINDING PROTEINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); RADIOLIGAND ASSAY; RATS; RECEPTORS, OPIOID, MU; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SUFENTANIL; TUMOR CELLS, CULTURED;

EID: 0030427024     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. ADAMS J. U., PARONIS C. A. AND HOLTZMAN S. G.: Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using β-funaltrexamine. J. Pharmacol. Exp. Ther. 255: 1027-1032, 1990.
2. BENOVJC J. L., STANISZEWSKI C., MAYOR F., CARON M. G. AND LEFKOWITZ R. J.: Activity of partial agonists for stimulation of adenylate cyclase correlates with ability to promote receptor phosphorylation. J. Biol. Chem. 263: 3893-3897, 1988.
3. BUTELMAN K. R., WINGER G., ZERNIG G. AND WOODS J. H.: Butorphanol: characterization of agonist and antagonist effects in rhesus monkeys. J. Pharmacol. Exp. Ther. 272: 845-853, 1995.
4. CARROLL J. A., MILLER L., SHAW J. S. AND DOWNES C. P.: Mu-receptor binding in physiological media: Comparison with isolated tissue data. Neuropeptides 5: 89-92, 1984.
5. o mediates the coupling of the μ opioid receptor to adenylyl cyclase in cloned neural cells and brain. Proc. Nat. Acad. Sci. U S A 90: 4062-4066, 1993a.
6. CARTER B. D. AND MEDZIHRADSKY F.: Receptor mechanisms of opioid tolerance in SH-SY5Y human neural cells. Mol. Pharmacol. 43: 465-473, 1993b.
7. 32P]GTP labeling of multiple G protein α subunits. J. Neurochem. 64: 2534-2543, 1995.
8. CHEN C. A. AND OKAYAMA H.: High efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7: 2745-2752, 1987.
9. CHEN Y., MESTEK A., LIU J., HURLEY J. A. AND YU L.: Molecular cloning and functional expression of a μ-opioid receptor from rat brain. Mol. Pharmacol. 44: 8-12, 1993a.
10. CHEN Y., MESTEK A., LIU J. AND YU L.: Molecular cloning of a rat κ opioid receptor reveals sequence similarities to the μ and δ opioid receptors. Biochem. J. 295: 625-628, 1993b.
11. CHENEY B. V., LAHTI R. A., BARSUHN C. AND GAY D. D.: An analysis of binding at the opioid receptor based upon an agonist/antagonist two-state model. Mol. Pharmacol. 22: 349-359, 1982.
12. 3-opioid receptors in the SH-SY5Y human neuroblastoma cell line. J. Neurochem. 65: 170-175, 1995.
13. CLARK M. J. AND MEDZIHRADSKY F.: Coupling of multiple opioid receptors to GTPase following selective receptor alkylation in brain membranes. Neuropharmacology 26: 1763-1770, 1987.
14. COLLIER H. O. J. AND ROY A. C.: Morphine-like drugs inhibit the stimulation by E prostaglandins of cyclic AMP formation by rat brain homogenates. Nature (Lond) 248: 24-27, 1874.
15. COSTA E. M., HOFFMAN B. B. AND LOEW G. H.: Opioid agonist binding and responses in SH-SY5Y cells. Life Sci. 50: 73-81, 1991.
16. COSTA T., OGINO Y., MUNSON P. J., ONARAN H. O. AND RODBARD D.: Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: Thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol. Pharmacol. 41: 549-560, 1992.
17. 2-adrenergic receptors to two G proteins with opposing effects. J. Biol. Chem. 267: 15795-15801, 1992.
18. EHLERT F. J.: The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. Mol. Pharmacol. 28: 410-421, 1985.
19. EMMERSON P. J., LIU M.-R., WOODS J. H. AND MEDZIHRADSKY F.: Binding affinity and selectivity of opioids at mu, delta, and kappa receptors in monkey brain membranes. J. Pharmacol. Exp. Ther. 271: 1630-1637, 1994.
20. EMMERSON P. J.: Opioid receptor binding and signal transduction: Modulation by the plasma membrane. (Abstract) Diss. Abst. Int. 56-12B: 6683, 1995.
21. EVANS C. J., KEITH D. E., MORRISON H., MAGENDZO K. AND EDWARDS R. H.: Cloning of a delta opioid receptor by functional expression. Science (Wash D C) 258: 495-499, 1992.
22. FISCHEL S. V. AND MEDZIHRADSKY F.: Scatchard analysis of opiate receptor binding. Mol. Pharmacol. 20: 269-279, 1981.
23. FRANCE C. P. AND WOODS J. H.: Discriminative stimulus effects of opioid agonists in morphine-dependent pigeons. J. Pharmacol. Exp. Ther. 254: 626-632, 1990.
24. FUKUDA K., KATO S., MORI K., NISHI M. AND TAKESHIMA H.: Primary structures and expression from cDNAs of rat opioid receptor δ and μ-subtypes. FEBS Lett. 327: 311-314, 1993.
25. 'GERAK L. R., BUTELMAN E. R., WOODS J. H. AND FRANCE C. P.: Antinociceptive and respiratory effects of nalbupine in rhesus monkeys. J. Pharmacol. Exp. Ther. 271: 993-999, 1994.
26. 1A receptor. Biochem. 33: 4283-4290, 1994.
27. GILMAN A. G.: G proteins: transducers of receptor-generated signals. Ann. Rev. Biochem. 56: 615-649, 1987.
28. GOLDSTEIN A. AND BARRETT R. W.: Ligand dissociation constants from competition binding assays: errors associated with ligand depletion. Mol. Pharmacol. 31: 603-609, 1987.
29. HERLING S. AND WOODS J. H.: Discriminative stimulus effects of narcotics: Evidence for multiple receptor-mediated actions. Life Sci. 28: 1571-1584, 1981.
30. o regulates neuronal calcium channels. Nature (Lond) 325: 445-447, 1987.
31. 2+ and the βγ-subunit complex on the interactions of guanine nucleotides with G proteins. J. Biol. Chem. 262: 762-766, 1987.
32. KAZMI S. M. I. AND MISHRA R. K.: Opioid receptors in human neuroblastoma SH-SY5Y cells: Evidence for distinct morphine (μ) and enkephalin (δ) binding sites. Biochem. Biophys. Res. Comm. 137: 813-820, 1986.
33. KENAKIN T.: Pharmacologic Analysis of Drug-Receptor Interaction. Raven Press Ltd, New York, 1993.
34. KENT R. S., DE LEAN A. AND LEFKOWITZ R. J.: A quantitative analysis of beta-adrenergic receptor interactions of high and low affinity states of the receptor by computer modeling of ligand binding data. Mol. Pharmacol. 17: 14-23, 1980.
35. KIEFFER B. L., BEFORT K., GAVERIAUX-RUFF C. AND HIRTH C.: The δ-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc. Nat. Acad. Sci. U S A 89: 12048-12052, 1992.
36. KLEE W. A. AND NIRENBERG F.: A neuroblastoma x glioma hybrid cell line with morphine receptors. Proc. Nat. Acad. Sci. U S A 71: 3474-3477, 1974.
37. KUROSE H., KATADA T., AMANO T. AND UI M.: Specific uncoupling by islet-activating protein, pertussis toxin, of negative signal transduction via α-adrenergic, cholinergic, and opiate receptors in neuroblastoma x glioma hybrid cells. J. Biol. Chem. 258: 4870-4875, 1983.
38. LAHTI R. A., FIGUR L. M., PIERCEY M. F., RIPPEL P. L. AND EVANS D. L.: Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: Utilization of receptor state binding affinities. Mol. Pharmacol. 42: 432-438, 1992.
39. LAUGWITZ K.-L., OFFERMANS S., SPICHER K. AND SCHULTZ G.: μ and δ opioid receptors differentially couple to G protein subtypes in membranes of human neuroblastoma SH-SY5Y cells. Neuron 10: 233-242, 1993.
40. LAW P.-Y., HOM D. S. AND LOH H. H.: Opiate regulation of adenosine 3′:5′-cyclic monophosphate level in neuroblastoma x glioma NG108-15 hybrid cells. Mol. Pharmacol. 23: 26-35, 1983.
41. LIMBIRD L. E.: Cell Surface Receptors: A Short Course on Theory and Methods. pp. 51-96, Marinus Nijhoff Publishing, Boston, 1986.
42. 35S]thio)-triphosphate binding. Mol. Pharmacol. 44: 115-123, 1993.
43. LOWRY O. H., ROSEBROUGH N. J., FARR A. L. AND RANDALL R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
44. MENG F., XIE G.-X., THOMPSON R. C., MANSOUR A., GOLDSTEIN A., WATSON S. J. AND AKIL H.: Cloning and pharmacological characterization of a rat κ opioid receptor. Proc. Nat. Acad. Sci. U S A 90: 9954-9958, 1993.
45. MJANGER E. AND YAKSH T. L.: Characteristics of dose-dependent antagonism by β-funaltrexamine of the antinociceptive effects of intrathecal mu agonists. J. Pharmacol. Exp. Ther. 258: 544-550, 1991.
46. MINAMI M., TOYA T., KATAO Y., MAEKAWA K., NAKAMURA S., ONOGI T., KANELO S. AND SATOH M.: Cloning and expression of a cDNA for the rat κ-opioid receptor. FEBS Lett. 329: 291-295, 1993.
47. otype GTP-binding protein. J. Neurosci. 14: 3842-3851, 1994.
48. PERT C. B. AND SNYDER S. H.: Opiate receptor binding of agonists and antagonists affected differentially by sodium. Mol. Pharmacol. 10: 868-879, 1974.
49. PICKER M. J., CRAFT R. M., NEGUS S. S., POWELL K. R., MATTOX S. R., JONES S. R., HARGROVE B. K. AND DYKSTRA L. A.: Intermediate efficacy mu opioids: Examination of their morphine-like stimulus effects and response rate-decreasing effects in morphine-tolerant rats. J. Pharmacol. Exp. Ther. 263: 668-681, 1992.
50. REMMERS A. AND MEDZIHRADSKY F.: Reconstitution of high-affinity opioid agonist binding in brain membranes. Proc. Nat. Acad. Sci. U S A 88: 2171-2175, 1991.
51. SAEKI S. AND YAKSH T. L.: Suppression of nociceptive responses by spinal mu opioid agonists: Effects of stimulus intensity and agonist efficacy. Anesth. Anal. 77: 265-274, 1993.
52. 2-adrenergic receptor J. Biol. Chem. 268: 4625-4636, 1993.
53. THOMPSON R. C., MANSOUR A., AKIL H. AND WATSON S. J.: Cloning and pharmacological characterization of a rat μ opioid receptor. Neuron 11: 903-913, 1993.
54. 2-adrenergic receptor activation of G proteins: Evidence for a precoupled receptor/G protein state. Mol. Pharmacol. 45: 524-531, 1994.
55. TOCQUÉ B., PFEIFFER A. AND KLEE A.: Transfer of functional opiate receptors from membranes to recipient cells by polyethylene glycol-induced fusion. FEBS Lett. 222: 327-331, 1987.
56. TOTA M. R. AND SCHIMERLIK M. I.: Partial agonist effects on the interaction between the atrial muscarinic receptor and the inhibitory guanine nucleotide-binding protein in a reconstituted system. Mol. Pharmacol. 37: 996-1004, 1990.
57. 35]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 47: 848-854, 1995.
58. TYERS M. B.: A classification of opiate receptors that mediate antinociception in animals. Br. J. Pharmacol. 69: 503-512, 1980.
59. WALKER E. A., BUTELMAN E. R., DECOSTA B. R. AND WOODS J. H.: Opioid thermal antinociception in rhesus monkeys: Receptor mechanisms and temperature dependency. J. Pharmacol. Exp. Ther. 267: 280-286, 1993.
60. 2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats. J. Pharmacol. Exp. Ther. 271: 959-968, 1994.
61. WANG J. B., IMAI Y., EPPLER C. M., GBEGOR P., SPIVAK C. E. AND UHL G. R.: μ opiate receptor: cDNA cloning and expression. Proc. Nat. Acad. Sci. U S A 90: 10230-10234, 1993.
62. WIELAND T. AND JAKOBS K. H.: Measurement of receptor-stimulated guanosine-5′-O-γ-thio)triphosphate binding by G proteins. Methods Enzymol. 237: 3-13, 1994.
63. WOODS J. H., FRANCE C. P., MEDZIHRADSKY F., SMITH C. B. AND WINGER G. D.: Evaluation of new compounds for opioid activity. In Problems of Drug Dependence, National Institute on Drug Abuse Research Monograph, 132, ed. by L. S. Harris, pp. 517-578, U.S. Government Printing Office, Washington, D.C., 1993.
64. YASUDA K., RAYNOR K., KONG H., BREDER C. D., TAKEDA J., REISINE T. AND BELL G. I.: Cloning and functional comparison of κ and δ opioid receptors form mouse brain. Proc. Nat. Acad. Sci. U S A 90: 6736-6740, 1993.
65. YOUNG A. M., STEPHENS K. R., HEIN D. W. AND WOODS J. H.: Reinforcing and discriminative stimulus properties of mixed agonist-antagonist opioids. J. Pharmacol. Ther. 229: 118-126, 1984.
66. YU V. C., RICHARDS M. L. AND SADEE W.: A human neuroblastoma cell line expresses μ and δ opioid receptor sites. J. Pharmacol. Exp. Ther. 261: 1065-1070, 1986.
67. YU V. C. AND SADEE W. J.: Efficacy and tolerance of narcotic analgesics at the mu opioid receptor in differentiated human neuroblastoma cells. Pharmacol. Exp. Ther. 245: 350-355, 1988.